What You Should Know:
- Variantyx, a Boston-based provider of high complexity hereditary disease testing, today announced that they secured $20M in funding for their Whole Genome Sequencing (WGS)-based testing methodology, an advanced genetic testing method currently used to diagnose rare inherited and neurological disorders. The series C funding round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Exscientia Secures $100M To Expand AI Drug Discovery Platform
What You Should Know:
- Exscientia, leading AI drug discovery company, today announced that it completed its $100 million Series C financing round, with a further $30 million investment from Blackrock.
- This new capital, which will be used to support Exscientia's platform development and proprietary pipeline, follows Exscientia’s demonstrated high growth, having announced earlier this year that the first ever precision engineered drug designed using AI had entered Phase I human clinical
Read More
Life Sciences Firm OrbiMed Raises $3.5B Across Private Investment Funds
What You Should Know:
Life sciences investment firm OrbiMed announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III.
The three new funds include a broad range of medical institutions, university endowments, foundations, pension funds and sovereign wealth funds.
- OrbiMed Private Investments
Read More
Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development
What You Should Know:
- Global biopharma company UCB and Microsoft announced today a new, multi-year strategic collaboration to advance UCB’s digital transformation, change the way care is delivered, and accelerate better outcomes for people living with severe diseases.
- The partnership builds on the companies’ joint work as part of the COVID Moonshot project which sought to create an orally bioavailable anti-viral for COVID-19. During the project, UCB completed six
Read More
Illumina, Sequoia Capital China Launches Genomics Incubator in China
What You Should Know:
- Illumina and Sequoia Capital will collaborate to build an ecosystem for life science startup companies advancing breakthrough applications in genomics.
- Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina will leverage the expertise of Illumina for Startups in building genomics companies with the unparalleled track record of Illumina Accelerator in San Francisco Bay Area and Cambridge, UK.
- Sequoia Capital China will dedicate to
Read More
Cellino Closes $16M Seed Financing led by The Engine and Khosla Ventures to Automate and Scale Stem Cell Manufacture
What You Should Know:
- Cellino, a Cambridge, MA-based personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the closing of a $16M Seed financing round. The round was co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC.
- The company’s platform solves a time-consuming, major bottleneck of developing drugs that rely on cell therapy, having to
Read More
Mammoth Biosciences, Agilent Partner on High-Throughput CRISPR-Based SARS-CoV-2 Diagnostic Test
What You Should Know:
- Mammoth Biosciences, the company bringing CRISPR out of the lab to help fight COVID-19 announced a partnership with lab giant Agilent to automate and scale its CRISPR-based high throughput testing system.
- Building on existing partnerships with Hamilton and Merck, this deal will help deliver a workflow capable of performing more than 4,000 COVID-19 tests per day.
Mammoth Biosciences, Inc. today announced a co-marketing agreement with Agilent Technologies to
Read More
AstraZeneca and Care Access Research Collaborate on Decentralized COVID-19 Clinical Trial
What You Should Know:
- AstraZeneca and Care Access Research are teaming up to
provide decentralized, mobile research site operations for AstraZeneca’s
AZD7442 phase III clinical trial in the US.
- The Phase III clinical trial called STORM CHASER will
assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and
pre-emptive treatment in approximately 1,125 participants in the US and UK.
Care Access Research, a decentralized research organization
(DRO) that operates as
Read More
West Virginia Launches Nation’s First Statewide COVID-19 Vaccine Distribution
What You Should Know:
- West Virginians will now have access to a COVID-19
vaccination pre-registration tool available statewide.
- West Virginia is the first state in the nation to deploy this new system through Everbridge, a global provider of critical event management technologies. The tool enables West Virginians to pre-register for COVID-19 vaccination and receive updates through text, phone, and/or email.
President Joe Biden has made it his priority to tackle COVID-19
Read More
Therma Fisher Acquires Rapid COVID-19 Test Provider Mesa Biotech for $450M
What You Should Know:
- Thermo
Fisher Scientific Inc. has entered into a definitive agreement to acquire
Mesa Biotech, Inc., a San Diego,
CA-based molecular diagnostic company, for approximately $450 million in cash.
Under the terms of the agreement, Thermo Fisher will pay up to an additional
$100 million in cash upon the completion of certain milestones following the
close of the transaction.
- Mesa Biotech designs, develops, manufactures, and commercializes next generation Rapid PCR
Read More
